Department of Psychology, Northwestern University, 2029 Sheridan Road Evanston, Chicago, IL, 60208, USA.
Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Neuropsychopharmacology. 2023 Jan;48(2):418-426. doi: 10.1038/s41386-022-01479-y. Epub 2022 Oct 25.
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs have shown promise in treating depressive disorders, perhaps by reversing deficits in reward processing in the brain. In addition, there are anecdotal reports that repeated ingestion of low doses of LSD, or "microdosing", improve mood, cognition, and feelings of wellbeing. However, the effects of low doses of classic psychedelics on reward processing have not been studied. The current study examined the effects of two single, low doses of LSD compared to placebo on measures of reward processing. Eighteen healthy adults completed three sessions in which they received placebo (LSD-0), 13 μg LSD (LSD-13) and 26 μg LSD (LSD-26) in a within-subject, double-blind design. Neural activity was recorded while participants completed the electrophysiological monetary incentive delay task. Event-related potentials were measured during feedback processing (Reward-Positivity: RewP, Feedback-P3: FB-P3, and Late-Positive Potential: LPP). Compared to placebo, LSD-13 increased RewP and LPP amplitudes for reward (vs. neutral) feedback, and LSD-13 and LSD-26 increased FB-P3 amplitudes for positive (vs. negative) feedback. These effects were unassociated with most subjective measures of drug effects. Thus, single, low doses of LSD (vs. placebo) increased three reward-related ERP components reflecting increased hedonic (RewP), motivational (FB-P3), and affective processing of feedback (LPP). These results constitute the first evidence that low doses of LSD increase reward-related brain activity in humans. These findings may have important implications for the treatment of depressive disorders.
经典迷幻剂作为治疗精神疾病的药物重新引起关注,这需要我们更深入地了解它们的神经机制。单一、高剂量的迷幻药物已显示出治疗抑郁症的潜力,这可能是通过逆转大脑中奖励处理的缺陷。此外,还有一些传闻报道称,重复摄入低剂量的 LSD,即“微剂量”,可以改善情绪、认知和幸福感。然而,经典迷幻剂低剂量对奖励处理的影响尚未得到研究。本研究考察了两种单一、低剂量 LSD 与安慰剂相比对奖励处理的影响。18 名健康成年人在一项内源性、双盲设计中完成了三个阶段,分别接受安慰剂(LSD-0)、13μg LSD(LSD-13)和 26μg LSD(LSD-26)。在参与者完成电生理学货币奖励延迟任务时记录神经活动。在反馈处理期间测量事件相关电位(奖励正性:RewP、反馈 P3:FB-P3 和晚期正性潜能:LPP)。与安慰剂相比,LSD-13 增加了奖励(vs. 中性)反馈的 RewP 和 LPP 振幅,LSD-13 和 LSD-26 增加了正性(vs. 负性)反馈的 FB-P3 振幅。这些效应与大多数药物效应的主观测量无关。因此,单一、低剂量的 LSD(与安慰剂相比)增加了三个与奖励相关的 ERP 成分,反映了愉悦感(RewP)、动机(FB-P3)和反馈的情感加工(LPP)的增加。这些结果构成了低剂量 LSD 增加人类奖励相关大脑活动的首个证据。这些发现可能对治疗抑郁症具有重要意义。